KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:待检查 入排置信度 0.98

Chemoradiotherapy and transanal endoscopic surgery versus transanal endoscopic surgery alone in T1N0M0 rectal cancer: a multicenter, randomized, controlled, phase III clinical trial (TAUTEM-T1 study).

Xavier Serra-Aracil, Anna Nonell, Cristina Gener-Jorge, Carles Pericay, Thomas Golda, Esther Kreisler, Eloy Espin-Basany, Anna Pallisera, Jesus Badia-Closa, Beatriz Espina, Nerea Borda-Arrizabalaga, Angel Reina, Hector Guadalajara-Labajo, Ana Otero, Salvadora Delgado, Miquel Kraft, Rosa Querol, Blas Flor, Gianluca Pellino, Sebastiano Biondo, Aleidis Caro-Tarrago, TAUTEM-T1 collaborative group

Int J Colorectal Dis 41(1) 96

PMID42026347
PMCIDPMC13236827
DOI10.1007/s00384-026-05112-y
发表日期2026-04-23
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
AI 判定该论文不进入自动 KM 提取:This record describes the design and rationale of a trial, not the results of a completed Phase III RCT.
摘要

摘要

PURPOSE: For clinical (c) T1N0M0 rectal adenocarcinoma without adverse pathological features, local excision by transanal endoscopic surgery (TEM) is standard; however, contemporary series still report local recurrence (LR) rates of 15-20%. Preoperative unfavorable histopathologic features cannot reliably identify high-risk pT1 disease, and both completion total mesorectal excision (TME) and salvage TME for LR carry relevant morbidity and functional impairment. Building on our prior phase III trial in T2-T3abN0M0 (TAUTEM study), showing that preoperative chemoradiotherapy (CRT) followed by TEM achieved a 7.4% LR with improved postoperative outcomes, we hypothesize that CRT + TEM will increase rectal preservation in cT1N0M0 without compromising oncologic safety or quality of life. The TAUTEM-T1 trial tests this hypothesis. METHODS: Multicenter, prospective, randomized, controlled, phase III superiority trial. Adults with biopsy-proven rectal low or moderate grade adenocarcinoma ≤ 4 cm, located < 10 cm from the anal verge, staged as cT1N0M0, are randomized (1:1) to: CRT (long-course radiotherapy with concurrent capecitabine) followed by TEM at week 10, or TEM alone. The primary endpoint is rectal preservation at 3 years. Secondary endpoints include postoperative morbidity/mortality, CRT-related adverse events, quality of life and anorectal function, and long-term oncologic outcomes (local/distant recurrence, overall and disease-free survival). Planned sample size: 106 patients. RESULTS: This manuscript describes the rationale and design of the TAUTEM-T1 randomized trial. CONCLUSION: TAUTEM-T1 will assess whether preoperative CRT followed by TEM increases rectal preservation in cT1N0M0 rectal cancer without compromising oncologic safety, quality of life, or bowel function. TRIAL REGISTRATION: ClinicalTrials.gov, NCT06450574.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。